Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. We herein report a case of osimertinib-induced interstitial lung disease (OsiILD) with an organizing pneumonia (OP) pattern and provide a literature-based review. Six months after osimertinib adminis...
Saved in:
| Published in | Internal Medicine Vol. 59; no. 6; pp. 823 - 828 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
The Japanese Society of Internal Medicine
15.03.2020
Japan Science and Technology Agency |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0918-2918 1349-7235 1349-7235 |
| DOI | 10.2169/internalmedicine.3689-19 |
Cover
| Abstract | Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. We herein report a case of osimertinib-induced interstitial lung disease (OsiILD) with an organizing pneumonia (OP) pattern and provide a literature-based review. Six months after osimertinib administration, a 75-year-old woman with right pleural carcinomatosis developed ILD with an OP pattern. After salvage chemotherapy, osimertinib with corticosteroid was successfully re-administered. A literature review suggested that 1) OsiILD with an OP pattern was rare but should be recognized, and 2) re-administration of osimertinib in OsiILD was successful in select patients. A criterion that determines whether a patient would benefit from re-administration is warranted. |
|---|---|
| AbstractList | Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. We herein report a case of osimertinib-induced interstitial lung disease (OsiILD) with an organizing pneumonia (OP) pattern and provide a literature-based review. Six months after osimertinib administration, a 75-year-old woman with right pleural carcinomatosis developed ILD with an OP pattern. After salvage chemotherapy, osimertinib with corticosteroid was successfully re-administered. A literature review suggested that 1) OsiILD with an OP pattern was rare but should be recognized, and 2) re-administration of osimertinib in OsiILD was successful in select patients. A criterion that determines whether a patient would benefit from re-administration is warranted.Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. We herein report a case of osimertinib-induced interstitial lung disease (OsiILD) with an organizing pneumonia (OP) pattern and provide a literature-based review. Six months after osimertinib administration, a 75-year-old woman with right pleural carcinomatosis developed ILD with an OP pattern. After salvage chemotherapy, osimertinib with corticosteroid was successfully re-administered. A literature review suggested that 1) OsiILD with an OP pattern was rare but should be recognized, and 2) re-administration of osimertinib in OsiILD was successful in select patients. A criterion that determines whether a patient would benefit from re-administration is warranted. Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. We herein report a case of osimertinib-induced interstitial lung disease (OsiILD) with an organizing pneumonia (OP) pattern and provide a literature-based review. Six months after osimertinib administration, a 75-year-old woman with right pleural carcinomatosis developed ILD with an OP pattern. After salvage chemotherapy, osimertinib with corticosteroid was successfully re-administered. A literature review suggested that 1) OsiILD with an OP pattern was rare but should be recognized, and 2) re-administration of osimertinib in OsiILD was successful in select patients. A criterion that determines whether a patient would benefit from re-administration is warranted. |
| Author | Hotta, Katsuyuki Higo, Hisao Itano, Junko Nishii, Kazuya Kiura, Katsuyuki Makimoto, Go Maeda, Yoshinobu Ohashi, Kadoaki Miyahara, Nobuaki |
| Author_xml | – sequence: 1 fullname: Hotta, Katsuyuki organization: Center for Innovative Clinical Medicine, Okayama University Hospital, Japan – sequence: 1 fullname: Makimoto, Go organization: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan – sequence: 1 fullname: Ohashi, Kadoaki organization: Department of Respiratory Medicine, Okayama University Hospital, Japan – sequence: 1 fullname: Nishii, Kazuya organization: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan – sequence: 1 fullname: Miyahara, Nobuaki organization: Department of Medical Technology, Okayama University Graduate School of Health Sciences, Japan – sequence: 1 fullname: Higo, Hisao organization: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan – sequence: 1 fullname: Maeda, Yoshinobu organization: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan – sequence: 1 fullname: Itano, Junko organization: Department of Respiratory Medicine, Okayama University Hospital, Japan – sequence: 1 fullname: Kiura, Katsuyuki organization: Department of Respiratory Medicine, Okayama University Hospital, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31787696$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUstu1DAUtVARnRZ-AVliwyYljp3EZoFUDa9KI1oVWFuOczNzRxlnsJ1W8EF8Jw6dDmXYsLmWfc85PvdxQo7c4IAQyvKzglXqFboI3pl-Ay1adHDGK6kyph6RGeNCZXXByyMyyxWTWZHCMTkJYZ3nXNaqeEKOOatlXalqRn5-Hq2FELqxp9eQmXaDDkP0JuLg6NDRy4Ab8DG9NhTdw2uGrh0ttPRichMiRjQ9XYxuSd9iABOA3mJcUZNYfmkc_sCUunIwbgaHhl6ZOFXxmp7T-QS-hu3gY4K3dIEpY-Lop9cbhNun5HFn-gDPducp-fr-3Zf5x2xx-eFifr7IbCl5zDomuTWqZrJSDaTChRANr60UXDaizkEplXPV2RykaDrVmrKqZNuxytiStYqfkjd3utuxSc214FIrer31uDH-ux4M6r8zDld6OdzomqWv6zoJvNwJ-OHbCCHqDQYLfW8cDGPQBS_ySjAhiwR9cQBdD-M01QklyyIXBRcJ9fyho72V-xH-sWz9EIKHTluMv8eXDGKvWa6nndGHO6OnndFsqlkeCNz_8R_UT3fUdYhmCXuiSRtie_iXWCpdTWEnsAfalfEaHP8FylfvIw |
| CitedBy_id | crossref_primary_10_1016_j_rmcr_2021_101450 crossref_primary_10_1111_1759_7714_14782 crossref_primary_10_1007_s10637_020_01005_1 crossref_primary_10_1007_s11523_024_01048_x crossref_primary_10_1007_s10637_020_00963_w crossref_primary_10_2169_internalmedicine_4877_24 crossref_primary_10_1111_1759_7714_14831 crossref_primary_10_2147_OTT_S475836 crossref_primary_10_1007_s40278_020_77602_5 crossref_primary_10_1111_1759_7714_15324 crossref_primary_10_1097_CAD_0000000000001436 |
| Cites_doi | 10.5414/CP201566 10.1001/jama.2014.3741 10.1111/cas.12550 10.4103/0366-6999.183426 10.1016/j.lungcan.2006.02.002 10.1016/j.lungcan.2014.09.015 10.2169/internalmedicine.8467-16 10.1056/NEJMoa1612674 10.1158/2159-8290.CD-14-0337 10.1007/s10637-016-0389-9 10.1016/j.resinv.2013.09.001 10.2169/internalmedicine.8947-17 10.1056/NEJMoa1411817 10.1016/j.jtho.2016.08.144 10.1016/j.jtho.2017.03.022 10.1016/j.jtho.2017.01.027 |
| ContentType | Journal Article |
| Copyright | 2020 by The Japanese Society of Internal Medicine Copyright Japan Science and Technology Agency 2020 Copyright © 2020 by The Japanese Society of Internal Medicine |
| Copyright_xml | – notice: 2020 by The Japanese Society of Internal Medicine – notice: Copyright Japan Science and Technology Agency 2020 – notice: Copyright © 2020 by The Japanese Society of Internal Medicine |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK 7U9 H94 K9. 7X8 5PM |
| DOI | 10.2169/internalmedicine.3689-19 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1349-7235 |
| EndPage | 828 |
| ExternalDocumentID | PMC7118377 31787696 10_2169_internalmedicine_3689_19 article_internalmedicine_59_6_59_3689_19_article_char_en |
| Genre | Journal Article Case Reports Report Case Study |
| GroupedDBID | --- 29J 2WC 5GY ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CS3 DIK DU5 EBS EJD F5P HYE JSF JSH M48 OK1 OVT P2P PGMZT RJT RNS RPM RZJ TR2 XSB AAYXX CITATION 7.U CGR CUY CVF ECM EIF M~E NPM 7T5 7TK 7U9 H94 K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c583t-f183ca971869be918444b37c8438b470e999039fc0e84bf9da5668df16ac51d93 |
| IEDL.DBID | M48 |
| ISSN | 0918-2918 1349-7235 |
| IngestDate | Thu Aug 21 13:48:47 EDT 2025 Fri Jul 11 09:08:27 EDT 2025 Sat Sep 20 14:21:11 EDT 2025 Thu Jan 02 22:54:40 EST 2025 Tue Jul 01 01:40:13 EDT 2025 Thu Apr 24 23:06:32 EDT 2025 Wed Sep 03 06:29:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | drug-induced ILD organizing pneumonia pattern re-administration reversed halo sign osimertinib |
| Language | English |
| License | The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c583t-f183ca971869be918444b37c8438b470e999039fc0e84bf9da5668df16ac51d93 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Report-1 ObjectType-Feature-4 content type line 23 ObjectType-Article-3 Correspondence to Dr. Kadoaki Ohashi, kohashi@cc.okayama-u.ac.jp |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2169/internalmedicine.3689-19 |
| PMID | 31787696 |
| PQID | 2385204234 |
| PQPubID | 2048449 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7118377 proquest_miscellaneous_2320641482 proquest_journals_2385204234 pubmed_primary_31787696 crossref_citationtrail_10_2169_internalmedicine_3689_19 crossref_primary_10_2169_internalmedicine_3689_19 jstage_primary_article_internalmedicine_59_6_59_3689_19_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-Mar-15 |
| PublicationDateYYYYMMDD | 2020-03-15 |
| PublicationDate_xml | – month: 03 year: 2020 text: 2020-Mar-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan – name: Tokyo |
| PublicationTitle | Internal Medicine |
| PublicationTitleAlternate | Intern. Med. |
| PublicationYear | 2020 |
| Publisher | The Japanese Society of Internal Medicine Japan Science and Technology Agency |
| Publisher_xml | – name: The Japanese Society of Internal Medicine – name: Japan Science and Technology Agency |
| References | 8. Miyauchi E, Ichinose M, Inoue A. Successful osimertinib rechallenge in a patient with T790M-mutant non-small cell lung cancer after osimertinib-induced interstitial lung disease. J Thorac Oncol 12: e59-e61, 2017. 22. Lee H, Lee HY, Sun JM, et al. Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication. J Thorac Oncol. Forthcoming. 10. Nagasaka M, Gadgeel SM. Retreatment with osimertinib following pneumonitis. Clin Lung Cancer. Forthcoming. 7. Mamesaya N, Kenmotsu H, Katsumata M, Nakajima T, Endo M, Takahashi T. Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody. Invest New Drugs 35: 105-107, 2017. 21. Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K. Transient asymptomatic pulmonary opacities during osimertinib treatment: "Stop or Go" Decision. J Thorac Oncol 11: 2051-2052, 2016. 3. Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA Study Phase II Extension Component. J Clin Oncol 35: 1288-1296, 2017. 13. Kiriu T, Tamura D, Tachihara M, et al. Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease. Intern Med 57: 91-95, 2018. 15. Yuan MK, Chang CY, Chang SC, et al. Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease. Int J Clin Pharmacol Ther 49: 587-593, 2011. 1. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311: 1998-2006, 2014. 11. Matsumoto Y, Kawaguchi T, Yamamoto N, et al. Interstitial lung disease induced by osimertinib for epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer. Intern Med 56: 2325-2328, 2017. 12. Takakuwa O, Oguri T, Uemura T, et al. Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: a case report. Mol Clin Oncol 7: 383-385, 2017. 4. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376: 629-640, 2017. 18. Yoshioka H, Komuta K, Imamura F, Kudoh S, Seki A, Fukuoka M. Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer. Lung Cancer 86: 201-206, 2014. 6. Nie KK, Zou X, Geng CX, et al. AZD9291-induced acute interstitial lung disease. Chin Med J (Engl) 129: 1507-1508, 2016. 17. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177: 1348-1357, 2008. 19. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4: 1046-1061, 2014. 20. Noonan SA, Sachs PB, Camidge DR. Transient asymptomatic pulmonary opacities occurring during osimertinib treatment. J Thorac Oncol 11: 2253-2258, 2016. 2. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372: 1689-1699, 2015. 9. Tachi H, Shiozawa T, Sakai C, et al. Osimertinib-induced interstitial lung disease presenting as eosinophilic pneumonia. J Thorac Oncol 12: e118-e120, 2017. 14. Endo M, Johkoh T, Kimura K, Yamamoto N. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 52: 135-140, 2006. 5. Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51: 260-277, 2013. 16. Gemma A, Kudoh S, Ando M, et al. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10708 Japanese patients with non-small-cell lung cancer. Cancer Sci 105: 1584-1590, 2014. 11 22 12 13 14 15 16 17 19 1 2 3 4 H Yoshioka (18) 2014; 86 5 6 7 8 9 20 10 21 |
| References_xml | – reference: 13. Kiriu T, Tamura D, Tachihara M, et al. Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease. Intern Med 57: 91-95, 2018. – reference: 1. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311: 1998-2006, 2014. – reference: 18. Yoshioka H, Komuta K, Imamura F, Kudoh S, Seki A, Fukuoka M. Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer. Lung Cancer 86: 201-206, 2014. – reference: 6. Nie KK, Zou X, Geng CX, et al. AZD9291-induced acute interstitial lung disease. Chin Med J (Engl) 129: 1507-1508, 2016. – reference: 19. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4: 1046-1061, 2014. – reference: 3. Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA Study Phase II Extension Component. J Clin Oncol 35: 1288-1296, 2017. – reference: 8. Miyauchi E, Ichinose M, Inoue A. Successful osimertinib rechallenge in a patient with T790M-mutant non-small cell lung cancer after osimertinib-induced interstitial lung disease. J Thorac Oncol 12: e59-e61, 2017. – reference: 20. Noonan SA, Sachs PB, Camidge DR. Transient asymptomatic pulmonary opacities occurring during osimertinib treatment. J Thorac Oncol 11: 2253-2258, 2016. – reference: 14. Endo M, Johkoh T, Kimura K, Yamamoto N. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 52: 135-140, 2006. – reference: 16. Gemma A, Kudoh S, Ando M, et al. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10708 Japanese patients with non-small-cell lung cancer. Cancer Sci 105: 1584-1590, 2014. – reference: 11. Matsumoto Y, Kawaguchi T, Yamamoto N, et al. Interstitial lung disease induced by osimertinib for epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer. Intern Med 56: 2325-2328, 2017. – reference: 17. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177: 1348-1357, 2008. – reference: 5. Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51: 260-277, 2013. – reference: 22. Lee H, Lee HY, Sun JM, et al. Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication. J Thorac Oncol. Forthcoming. – reference: 4. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376: 629-640, 2017. – reference: 12. Takakuwa O, Oguri T, Uemura T, et al. Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: a case report. Mol Clin Oncol 7: 383-385, 2017. – reference: 21. Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K. Transient asymptomatic pulmonary opacities during osimertinib treatment: "Stop or Go" Decision. J Thorac Oncol 11: 2051-2052, 2016. – reference: 7. Mamesaya N, Kenmotsu H, Katsumata M, Nakajima T, Endo M, Takahashi T. Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody. Invest New Drugs 35: 105-107, 2017. – reference: 2. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372: 1689-1699, 2015. – reference: 15. Yuan MK, Chang CY, Chang SC, et al. Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease. Int J Clin Pharmacol Ther 49: 587-593, 2011. – reference: 9. Tachi H, Shiozawa T, Sakai C, et al. Osimertinib-induced interstitial lung disease presenting as eosinophilic pneumonia. J Thorac Oncol 12: e118-e120, 2017. – reference: 10. Nagasaka M, Gadgeel SM. Retreatment with osimertinib following pneumonitis. Clin Lung Cancer. Forthcoming. – ident: 17 – ident: 3 – ident: 15 doi: 10.5414/CP201566 – ident: 1 doi: 10.1001/jama.2014.3741 – ident: 16 doi: 10.1111/cas.12550 – ident: 6 doi: 10.4103/0366-6999.183426 – ident: 14 doi: 10.1016/j.lungcan.2006.02.002 – volume: 86 start-page: 201 issn: 0169-5002 year: 2014 ident: 18 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2014.09.015 – ident: 12 – ident: 11 doi: 10.2169/internalmedicine.8467-16 – ident: 4 doi: 10.1056/NEJMoa1612674 – ident: 10 – ident: 19 doi: 10.1158/2159-8290.CD-14-0337 – ident: 7 doi: 10.1007/s10637-016-0389-9 – ident: 5 doi: 10.1016/j.resinv.2013.09.001 – ident: 13 doi: 10.2169/internalmedicine.8947-17 – ident: 2 doi: 10.1056/NEJMoa1411817 – ident: 20 doi: 10.1016/j.jtho.2016.08.144 – ident: 9 doi: 10.1016/j.jtho.2017.03.022 – ident: 8 doi: 10.1016/j.jtho.2017.01.027 – ident: 21 – ident: 22 |
| SSID | ssj0038792 |
| Score | 2.3092687 |
| Snippet | Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. We herein report a case of osimertinib-induced... |
| SourceID | pubmedcentral proquest pubmed crossref jstage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 823 |
| SubjectTerms | Acrylamides - administration & dosage Acrylamides - adverse effects Acrylamides - therapeutic use Adenocarcinoma - drug therapy Aged Aniline Compounds - administration & dosage Aniline Compounds - adverse effects Aniline Compounds - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Case Report Case reports Chemotherapy Corticosteroids drug-induced ILD Epidermal growth factor receptors ErbB Receptors - genetics Female Humans Internal medicine Literature reviews Lung diseases Lung Diseases, Interstitial - chemically induced Lung Neoplasms - drug therapy Mutants organizing pneumonia pattern osimertinib Pneumonia Pneumonia - chemically induced Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use re-administration reversed halo sign Salvage Therapy |
| Title | Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review |
| URI | https://www.jstage.jst.go.jp/article/internalmedicine/59/6/59_3689-19/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/31787696 https://www.proquest.com/docview/2385204234 https://www.proquest.com/docview/2320641482 https://pubmed.ncbi.nlm.nih.gov/PMC7118377 |
| Volume | 59 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Internal Medicine, 2020/03/15, Vol.59(6), pp.823-828 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3_a9UwEA9jiviL-H3VOSL4a2bbJE0iiIzpnLrpUB_st5ImqVaefbq9gv5D_p3eNW3Zm0PEXwqP3qWP3CX3udzljpBHqcwBsnnFgpOcCRA6s3las6ww0gaeGt13UTh8W-zPxOtjebxGxuuKwwSeXujaYT-p2cl8-8f3n89gwT_FNGYY83ETz87mYzR6mxfaMKwFeqmPGmFCn5hiC1yrvlUyGEq8f5DpmN_z15FWjNblL4DbPoWLIOn5zMozpmrvOrk2YEy6E5XiBlkL7U1y5XD42i3y60PXt0msuzl9H5hdqZ9LFzV9d9p8xXzrtqlo0579ycCFB2XwtD9JxDwD0F96ADsGfR5DPRRPdqkFrnjLE0wjPWpDB-reWHrUl_Nsn9AduovEEf8DuacHU4FnGgMWt8ls78XH3X029GtgTmq-ZDVsD84ahV2uqgAzK4SouHJacF0JlQYAoyk3tUuDFlVtvAUsqX2dFdbJzBt-h6y3izZsEAo4KwgPI6XKgwcK7n8mfS1l7ZW32rmEqFEgpRuKmWNPjXkJTg2KsjwvyhJFWWYmIdnE-S0W9PgHnpdR5hPHsKz_5JCmLPAxcE6EeIcONqKEbI5KU466XgJqkjnmJ4mEPJxewzLH2I1tw6JDmhzAIxZtTcjdqGPTnwEICDbNFDApK9o3EWAJ8dU3bfO5LyWuwL_kSt37j0m5T67mePaAuY1yk6wvT7rwAADastoC1-TVm61-1f0GXiZFiQ |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Successful+Re-administration+of+Osimertinib+in+Osimertinib-induced+Interstitial+Lung+Disease+with+an+Organizing+Pneumonia+Pattern%3A+A+Case+Report+and+Literature+Review&rft.jtitle=Internal+medicine+%28Tokyo%2C+1992%29&rft.au=Itano%2C+Junko&rft.au=Higo%2C+Hisao&rft.au=Ohashi%2C+Kadoaki&rft.au=Makimoto%2C+Go&rft.date=2020-03-15&rft.issn=0918-2918&rft.eissn=1349-7235&rft.volume=59&rft.issue=6&rft.spage=823&rft.epage=828&rft_id=info:doi/10.2169%2Finternalmedicine.3689-19&rft.externalDBID=n%2Fa&rft.externalDocID=10_2169_internalmedicine_3689_19 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-2918&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-2918&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-2918&client=summon |